Ionizable Lipid Nanoparticle-Mediated TRAIL MRNA Delivery in the Tumor Microenvironment to Inhibit Colon Cancer Progression

Introduction: Immunotherapy has revolutionized cancer treatment by harnessing the immune system to enhance antitumor responses while minimizing off-target effects. Among the promising cancer-specific therapies, tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has attracted significant attention.

Methods: Here, we developed an ionizable lipid nanoparticle (LNP) platform to deliver TRAIL mRNA (LNP-TRAIL) directly to the tumor microenvironment (TME) to induce tumor cell death. Our LNP-TRAIL was formulated via microfluidic mixing and the induction of tumor cell death was assessed in vitro. Next, we investigated the ability of LNP-TRAIL to inhibit colon cancer progression in vivo in combination with a TME normalization approach using Losartan (Los) or angiotensin 1-7 (Ang(1-7)) to reduce vascular compression and deposition of extracellular matrix in mice.

Results: Our results demonstrated that LNP-TRAIL induced tumor cell death in vitro and effectively inhibited colon cancer progression in vivo, particularly when combined with TME normalization induced by treatment Los or Ang(1-7). In addition, potent tumor cell death as well as enhanced apoptosis and necrosis was found in the tumor tissue of a group treated with LNP-TRAIL combined with TME normalization.

Discussion: Together, our data demonstrate the potential of the LNP to deliver TRAIL mRNA to the TME and to induce tumor cell death, especially when combined with TME normalization. Therefore, these findings provide important insights for the development of novel therapeutic strategies for the immunotherapy of solid tumors.

Citing Articles

Selective phosphodiesterase 4 inhibitor roflumilast reduces inflammation and lung injury in models of betacoronavirus infection in mice.

Beltrami V, Martins F, Martins D, Queiroz-Junior C, Felix F, Resende L Inflamm Res. 2025; 74(1):24.

PMID: 39862252 DOI: 10.1007/s00011-024-01985-3.

TRAIL as a Warrior in Nano-Sized Trojan Horse: Anticancer and Anti-Metastatic Effects of Nano-Formulations of TRAIL in Cell Culture and Animal Model Studies.

Farooqi A, Turgambayeva A, Kamalbekova G, Suleimenova R, Latypova N, Ospanova S Medicina (Kaunas). 2025; 60(12.

PMID: 39768856 PMC: 11677168. DOI: 10.3390/medicina60121977.

Progress and prospects of mRNA-based drugs in pre-clinical and clinical applications.

Shi Y, Shi M, Wang Y, You J Signal Transduct Target Ther. 2024; 9(1):322.

PMID: 39543114 PMC: 11564800. DOI: 10.1038/s41392-024-02002-z.

Better, Faster, Stronger: Accelerating mRNA-Based Immunotherapies With Nanocarriers.

Carvalho H, Fidalgo T, Acurcio R, Matos A, Satchi-Fainaro R, Florindo H Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2024; 16(6):e2017.

PMID: 39537215 PMC: 11655444. DOI: 10.1002/wnan.2017.

Targeting Death Receptor 5 (DR5) for the imaging and treatment of primary bone and soft tissue tumors: an update of the literature.

Gamie Z, Krippner-Heidenreich A, Gerrand C, Rankin K Front Mol Biosci. 2024; 11:1384795.

PMID: 39286782 PMC: 11402684. DOI: 10.3389/fmolb.2024.1384795.

References

Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C . Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006; 313(5795):1960-4. DOI: 10.1126/science.1129139. View

Jain R . Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. J Clin Oncol. 2013; 31(17):2205-18. PMC: 3731977. DOI: 10.1200/JCO.2012.46.3653. View

Soto-Pantoja D, Menon J, Gallagher P, Tallant E . Angiotensin-(1-7) inhibits tumor angiogenesis in human lung cancer xenografts with a reduction in vascular endothelial growth factor. Mol Cancer Ther. 2009; 8(6):1676-83. PMC: 3314264. DOI: 10.1158/1535-7163.MCT-09-0161. View

Raman D, Tay P, Hirpara J, Liu D, Pervaiz S . TRAIL sensitivity of nasopharyngeal cancer cells involves redox dependent upregulation of TMTC2 and its interaction with membrane caspase-3. Redox Biol. 2021; 48:102193. PMC: 8636823. DOI: 10.1016/j.redox.2021.102193. View

Chauhan V, Martin J, Liu H, Lacorre D, Jain S, Kozin S . Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels. Nat Commun. 2013; 4:2516. PMC: 3806395. DOI: 10.1038/ncomms3516. View

Scalzo S, Santos A, Ferreira H, Costa P, Prazeres P, da Silva N . Ionizable Lipid Nanoparticle-Mediated Delivery of Plasmid DNA in Cardiomyocytes. Int J Nanomedicine. 2022; 17:2865-2881. PMC: 9252585. DOI: 10.2147/IJN.S366962. View

Warth A, Cortis J, Soltermann A, Meister M, Budczies J, Stenzinger A . Tumour cell proliferation (Ki-67) in non-small cell lung cancer: a critical reappraisal of its prognostic role. Br J Cancer. 2014; 111(6):1222-9. PMC: 4453847. DOI: 10.1038/bjc.2014.402. View

Seidel J, Otsuka A, Kabashima K . Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations. Front Oncol. 2018; 8:86. PMC: 5883082. DOI: 10.3389/fonc.2018.00086. View

Chappell M, Al Zayadneh E . Angiotensin-(1-7) and the Regulation of Anti-Fibrotic Signaling Pathways. J Cell Signal (Los Angel). 2017; 2(1). PMC: 5501273. DOI: 10.4172/2576-1471.1000134. View

10.

Kather J, Halama N . Harnessing the innate immune system and local immunological microenvironment to treat colorectal cancer. Br J Cancer. 2019; 120(9):871-882. PMC: 6734657. DOI: 10.1038/s41416-019-0441-6. View

11.

Simoni Y, Becht E, Fehlings M, Loh C, Koo S, Teng K . Bystander CD8 T cells are abundant and phenotypically distinct in human tumour infiltrates. Nature. 2018; 557(7706):575-579. DOI: 10.1038/s41586-018-0130-2. View

12.

Li H, Anton van der Merwe P, Sivakumar S . Biomarkers of response to PD-1 pathway blockade. Br J Cancer. 2022; 126(12):1663-1675. PMC: 9174485. DOI: 10.1038/s41416-022-01743-4. View

13.

Mitchell M, Webster J, Chung A, Guimaraes P, Khan O, Langer R . Polymeric mechanical amplifiers of immune cytokine-mediated apoptosis. Nat Commun. 2017; 8:14179. PMC: 5364380. DOI: 10.1038/ncomms14179. View

14.

de Miguel D, Gallego-Lleyda A, Anel A, Martinez-Lostao L . Liposome-bound TRAIL induces superior DR5 clustering and enhanced DISC recruitment in histiocytic lymphoma U937 cells. Leuk Res. 2015; 39(6):657-66. DOI: 10.1016/j.leukres.2015.03.019. View

15.

Di Trani C, Cirella A, Arrizabalaga L, Alvarez M, Bella A, Fernandez-Sendin M . Intratumoral injection of IL-12-encoding mRNA targeted to CSFR1 and PD-L1 exerts potent anti-tumor effects without substantial systemic exposure. Mol Ther Nucleic Acids. 2023; 33:599-616. PMC: 10450355. DOI: 10.1016/j.omtn.2023.07.020. View

16.

Wajant H, Moosmayer D, Wuest T, Bartke T, Gerlach E, Schonherr U . Differential activation of TRAIL-R1 and -2 by soluble and membrane TRAIL allows selective surface antigen-directed activation of TRAIL-R2 by a soluble TRAIL derivative. Oncogene. 2001; 20(30):4101-6. DOI: 10.1038/sj.onc.1204558. View

17.

Goel S, Duda D, Xu L, Munn L, Boucher Y, Fukumura D . Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev. 2011; 91(3):1071-121. PMC: 3258432. DOI: 10.1152/physrev.00038.2010. View

18.

Batchelor T, Gerstner E, Emblem K, Duda D, Kalpathy-Cramer J, Snuderl M . Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation. Proc Natl Acad Sci U S A. 2013; 110(47):19059-64. PMC: 3839699. DOI: 10.1073/pnas.1318022110. View

19.

Jain R . Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia. Cancer Cell. 2014; 26(5):605-22. PMC: 4269830. DOI: 10.1016/j.ccell.2014.10.006. View

20.

Jana S, Hsieh A, Gupta R . Reciprocal amplification of caspase-3 activity by nuclear export of a putative human RNA-modifying protein, PUS10 during TRAIL-induced apoptosis. Cell Death Dis. 2017; 8(10):e3093. PMC: 5682645. DOI: 10.1038/cddis.2017.476. View